VistaGen Therapeutics

$2.44
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.06 (-2.43%) Today
+$0.03 (+1.24%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell VTGN and other stocks, options, and ETFs commission-free!

About VTGN

VistaGen Therapeutics, Inc. Common Stock, also called VistaGen Therapeutics, is a clinical-stage biopharmaceutical company committed to developing and commercializing new generation medications that go beyond the current standard of care for anxiety, depression and other central nervous system (CNS) disorders. The company's portfolio includes PH94B, a neuroactive nasal spray with potential to treat multiple anxiety disorders that the company is currently preparing for Phase III clinical trial for social anxiety disorder (SAD), PH10, a neuroactive nasal spray that the company is planning for Phase 2b development as a stand-alone treatment for major depressive disorder (MDD), and AV-101 which the Company is developing for the treatment of major depressive disorder (MDD), suicidal ideation, neuropathic pain, levodopa-induced dyskinesia (LID) and epilepsy. The company was founded by H. Ralph Snodgrass and Gordon Keller on May 26, 1998 and is headquartered in South San Francisco, CA. The listed name for VTGN is VistaGen Therapeutics, Inc. Common Stock.

CEO
Shawn K. Singh
Employees
9
Headquarters
South San Francisco, California
Founded
1998
Market Cap
384.75M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
9.59M
High Today
$2.58
Low Today
$2.38
Open Price
$2.56
Volume
2.70M
52 Week High
$3.18
52 Week Low
$0.30

VTGN Earnings

-$0.15
-$0.10
-$0.05
$0.00
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Q1 FY21
Q2 FY21
Q3 FY21
Q4 FY21
Estimated
— per share
Actual
Expected Jun 28, After Hours

You May Also Like

RAAS
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure